Temozolomide in children with progressive low-grade glioma

We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma. Thirty eligible patients were enrolled on this study. Median age at enrollment was 10 years (range, 4–18 years). Eligible patients received TMZ (200 mg/m(2) per day) by mout...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Gururangan, Sridharan, Fisher, Michael J., Allen, Jeffrey C., Herndon, James E., Quinn, Jennifer A., Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Phillips, Peter C., Watral, Melody A., Krauser, Jeanne M., Friedman, Allan H., Friedman, Henry S.
פורמט: Artigo
שפה:Inglês
יצא לאור: Duke University Press 2007
נושאים:
Special Focus: Pediatric Neuro-Oncology
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC1871667/
https://ncbi.nlm.nih.gov/pubmed/17347491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2006-030
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים